Pharmathen

Pharmathen is a leading, privately-held developer of advanced generic drug delivery systems, with a strong emphasis on complex formulations like long-acting injectables (LAI). It leverages three certified technology platforms to drive a pipeline of over 40 products and a commercial portfolio of 100+ products, generating revenue through global partnerships and direct sales. With over 1,700 employees and significant annual R&D investment (~€35M), the company is a major R&D investor in Greece and aims to improve patient access to affordable, innovative medicines worldwide.

Three fully certified technological platforms for Long-Acting Therapeutic Technologies (LATTs), including platforms for long-acting injectables (LAI), sustained release, and ophthalmic formulations.

Pharmathen competes in the niche but growing market for complex generics and drug delivery systems, facing competition from other specialized developers like Viatris (formerly Mylan's complex generics division), Hikma's specialty segment, and smaller R&D-focused firms. Its vertically integrated model and certified technology platforms are key differentiators.